Results from a phase 2 study of ibrutinib have furthermore revealed promising results in a subgroup of ABC DLBCL, where the mutational status of pathways involved in NF-κB activation may be useful for predicting response to BTK inhibition. Here, NFKB1 is linked to diffuse large B-cell lymphoma.